Travere Therapeutics (NASDAQ:TVTX) Given Buy Rating at HC Wainwright

Travere Therapeutics (NASDAQ:TVTX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $30.00 price objective on the stock. HC Wainwright's price objective points to a potential upside of 100.00% from the stock's current price. HC Wainwright also issued estimates for Travere Therapeutics' Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.47 EPS.

Several other brokerages also recently weighed in on TVTX. Wedbush reaffirmed an "outperform" rating and set a $30.00 price target on shares of Travere Therapeutics in a report on Friday, May 16th. Guggenheim restated a "buy" rating and issued a $47.00 target price on shares of Travere Therapeutics in a research note on Monday, April 14th. Stifel Nicolaus boosted their price target on shares of Travere Therapeutics from $22.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, May 2nd. Bank of America increased their price target on shares of Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Finally, Scotiabank restated an "outperform" rating on shares of Travere Therapeutics in a research report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics has an average rating of "Moderate Buy" and an average target price of $32.14.

Travere Therapeutics Stock Performance

Shares of TVTX traded up $0.16 during mid-day trading on Tuesday, hitting $15.00. 663,493 shares of the company's stock were exchanged, compared to its average volume of 1,616,530. The company has a current ratio of 2.05, a quick ratio of 2.03 and a debt-to-equity ratio of 9.46. Travere Therapeutics has a fifty-two week low of $7.72 and a fifty-two week high of $25.29. The business's 50 day moving average is $16.72 and its two-hundred day moving average is $18.13. The firm has a market capitalization of $1.33 billion, a P/E ratio of -5.34 and a beta of 0.72.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,179.73% and a negative net margin of 82.88%. The firm had revenue of $81.73 million during the quarter, compared to the consensus estimate of $77.44 million. During the same period in the prior year, the business earned ($1.76) EPS. The firm's revenue was up 83.3% compared to the same quarter last year. On average, equities analysts expect that Travere Therapeutics will post -1.4 earnings per share for the current year.

Insider Transactions at Travere Therapeutics

In related news, CFO Christopher R. Cline sold 1,784 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $37,553.20. Following the sale, the chief financial officer owned 93,126 shares in the company, valued at $1,960,302.30. This represents a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Eric M. Dube sold 18,924 shares of Travere Therapeutics stock in a transaction on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $398,350.20. Following the transaction, the chief executive officer directly owned 419,173 shares of the company's stock, valued at approximately $8,823,591.65. This represents a 4.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,342 shares of company stock valued at $485,753 in the last quarter. 4.19% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TVTX. US Bancorp DE grew its holdings in shares of Travere Therapeutics by 323.4% during the fourth quarter. US Bancorp DE now owns 31,795 shares of the company's stock worth $554,000 after buying an additional 24,286 shares in the last quarter. Northern Trust Corp raised its holdings in Travere Therapeutics by 11.3% in the fourth quarter. Northern Trust Corp now owns 754,395 shares of the company's stock valued at $13,142,000 after buying an additional 76,358 shares during the period. Wellington Management Group LLP purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at $583,000. Swiss National Bank lifted its stake in shares of Travere Therapeutics by 12.8% during the fourth quarter. Swiss National Bank now owns 151,900 shares of the company's stock worth $2,646,000 after purchasing an additional 17,200 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Travere Therapeutics by 5,072.9% during the 1st quarter. GAMMA Investing LLC now owns 10,501 shares of the company's stock worth $188,000 after acquiring an additional 10,298 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.